Credit rating agency, ICRA has reaffirmed the ‘AA+’ rating outstanding on the Rs 20 crore fund based facilities and Rs 27 crore non-fund based facilities of Biocon. The outlook on the long term rating is stable. The rating agency has also reaffirmed the ‘A1+’ rating outstanding on the Rs 203 crore (inter fund based changeable) facilities of Biocon.
The reaffirmation in ratings continues to take into account the company’s strong business profile with an integrated presence spanning research and development (R&D), manufacturing and marketing, the company’s comfortable financial position and its diversified revenue stream.
Biocon is India’s largest and Asia's leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: